Search clinical trials for: Glucagon receptor antagonist

Total 41824 results

Mayo Clinic
Novo Nordisk A/S

Active, not recruiting

Effect of GLP-1 Receptor Agonism After Sleeve Gastrectomy

Obesity

United States
Cedars-Sinai Medical Center
Novo Nordisk A/S; The Cure Parkinson's Trust

Completed

Safety and Efficacy of Liraglutide in Parkinson's Disease

Parkinson Disease

United States
Milton S. Hershey Medical Center
National Institute on Drug Abuse (NIDA); National Institutes of Health (NIH)

Completed

Use of a GLP-1R Agonist to Treat Opioid Use Disorder

Opioid-Related Disorders | Opiate Substitution Treatment

United States
Hospital de Clinicas de Porto Alegre

Completed

The Use of Liraglutide in Brain Death

Brain Death

Brazil
The University of Texas Health Science Center at...

Suspended

Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in T2DM

Type 2 Diabetes | Insulin Sensitivity | Glucose Tolerance Impaired

United States
Boehringer Ingelheim

Completed

A Study Using Medical Records of Danish People With Type 2 Diabetes Comparing Empagliflozin and Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) in the Occurrence of Serious Cardiovascular Outcomes

Diabetes Mellitus, Type 2

Denmark
Eli Lilly and Company

Completed

A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin (SURPASS-6)

Type 2 Diabetes

United States, Puerto Rico, Spain, Germany, Argentina, Brazil, Turkey, Hungary, Italy, Russian Federation, Slovakia, Belgium, Czechia, Greece, Mexico, Romania
Mayo Clinic
Patient-Centered Outcomes Research Institute

Active, not recruiting

Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk

Type 2 Diabetes | Cardiac Disease

United States
Boehringer Ingelheim

Completed

Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney Disease

Diabetes Mellitus, Type 2

United States
University of Maryland, Baltimore

Terminated

Pharmacogenomics of GLP1 Receptor Agonists

Type 2 Diabetes

United States
University of Pennsylvania

Suspended

Glucagon-like Peptide-1 Metabolism and Acute Neprilysin Inhibition

Hypertension | Diabetes Mellitus, Type 2 | Pre-diabetic | Elevated Blood Pressure

United States
University of Florida
National Institute of Neurological Disorders and Stroke (NINDS)

Completed

Effects of Exenatide on Motor Function and the Brain

Parkinson's Disease

United States
Sanofi
Antaros Medical

Completed

A Clinical Study to Investigate if SAR425899 Binds to the Liver and Pancreas in Overweight to Obese Type 2 Diabetes Mellitus Patients

Type 2 Diabetes Mellitus

Sweden
Eli Lilly and Company

Completed

A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes (SURPASS-2)

Type 2 Diabetes

United States, Puerto Rico, Australia, United Kingdom, Mexico, Argentina, Brazil, Israel, Canada
Eli Lilly and Company

Completed

A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin (SURPASS-5)

Type 2 Diabetes

United States, Puerto Rico, Spain, Japan, Germany, Czechia, Poland, Slovakia
Eli Lilly and Company

Completed

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone (SURPASS-1)

Type 2 Diabetes Mellitus

United States, Japan, India, Puerto Rico, Mexico
Assistance Publique - Hôpitaux de Paris

Completed

Effect of GLP-1 on Angiogenesis (ANGIOSAFE 1)

Type 2 Diabetes

France
Duke University

Terminated

A Study to Determine Safety and Efficacy of (REMD-477) in Controlling Hyperglycemia Due to Copanlisib

Hyperglycemia Drug Induced

United States
David D'Alessio, M.D.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Glucagon Regulation of Glucose Metabolism

Insulin Secretion

United States
University Hospital, Gentofte, Copenhagen
Eli Lilly and Company

Enrolling by invitation

Delineation of the Diabetogenic Role of Extrapancreatic Glucagon in Totally Pancreatectomised Patients Using Glucagon Receptor Antagonism (PX-GRA)

Diabetes After Total Pancreatectomy
University of Copenhagen
Hvidovre University Hospital

Completed

Effect of Neprilysin on Glucagon-Like Peptide-1 in Patients With Type 2 Diabetes (NEPT2D)

Type2 Diabetes

Denmark
University of Athens

Completed

Effects of Agonists of Glucagon Like Peptide - 1 Receptors (GLP-1R) on Arterial Stiffness, Endothelial Glycocalyx and Coronary Flow Reserve in Patients With Coronary Artery Disease and Patients With Diabetes Mellitus

Coronary Artery Disease | Type 2 Diabetes Mellitus

Greece
Radboud University Medical Center
University of Coimbra

Unknown

Glucagon Like Peptide 1 Receptor (GLP1R) Expression and Beta-cell Mass in Patients With Type 2 Diabetes (GLP1R-T2D)

Diabetes Mellitus, Type 2 | Diabetes Mellitus

Netherlands
GlaxoSmithKline
PPD

Completed

Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Spain, Germany, Hungary, Italy, Philippines, France, United States, Mexico, Brazil, South Africa, Korea, Republic of, Canada, Poland, United Kingdom
University Hospital Bispebjerg and Frederiksberg

Completed

Glucagon's Cardiovascular Effects With and Without Beta-blocker-induced Cardioinhibition (GLUCAGON)

Drug Overdose | Overdose of Beta-adrenergic Blocking Drug

Denmark
Eli Lilly and Company
Locemia Solutions ULC

Completed

A Study of Nasal Glucagon in Participants With a Common Cold

Common Cold

Canada
Peking Union Medical College Hospital

Unknown

Metformin vs Metformin Combined With GLP-1RA (Glucagon-like Peptide 1 Receptor Agonist) on Overweight/Obese PCOS Patients

Polycystic Ovary Syndrome

China
Nicolai Jacob Wewer Albrechtsen

Completed

The Effects of Neprilysin on Glucagon-like Peptide-1 (NEP)

Heart Failure | Diabetes

Denmark
University of Padova
Azienda Ospedaliera di Padova

Unknown

GLP-1 REceptor Agonists and Real World EvIdeNce (GLP-1REWIN)

Type 2 Diabetes

Italy
GlaxoSmithKline
Duke Clinical Research Institute

Completed

Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus

United States, Argentina, Germany, Poland, Russian Federation, Spain, Taiwan, Czechia, Hungary, Italy, Ukraine, Belgium, Netherlands, South Africa, Sweden, Thailand, Korea, Republic of, Mexico, Bulgaria, Hong Kong, Peru, Philippines, Gree... and more
Karl Neff
University College Dublin

Completed

The Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Diabetic Kidney Disease

Diabetic Kidney Disease

Ireland
Sun Yat-sen University

Completed

Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects (LIGHT-ON)

Non-alcoholic Fatty Liver Disease

China
University of Minnesota
GlaxoSmithKline

Completed

Efficacy of Coreg CR and Lisinopril on Markers for Cardiovascular Functional and Structural Disease (DETECT)

Pre-hypertension

United States
Seoul National University Hospital
Daewoong Pharmaceutical Co. LTD.

Completed

The Effect of Combination of Mosapride and DPP-4 Inhibitor on Plasma Concentration of Incretin Hormones

Diabetes Mellitus, Type 2

Korea, Republic of
University of Chicago

Completed

Incretin Regulation of Insulin Secretion in Monogenic Diabetes

Monogenic Diabetes

United States
AstraZeneca

Completed

Clinical Outcomes of Exenatide Versus Basal Insulin

Type 2 Diabetes

United Kingdom
Christina Kruuse

Completed

The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Non-stroke Volunteers (EGRABINS1)

Stroke

Denmark
The First Hospital of Jilin University

Unknown

A Study of the Effect of Glucagon-like Peptide 1(GLP-1) Receptor Agonist in Combination With Metformin Therapy on Diabetes Remission in Subjects With Newly Diagnosed Type 2 Diabetes Who Are Overweight or Obese

Diabetes Mellitus, Type 2

China
Diabeteszentrum Bad Lauterberg im Harz

Completed

GLP-1 Mediating DPP-4 Inhibition in Type 2 Diabetes

Type 2 Diabetes

Germany
Sandwell & West Birmingham Hospitals NHS Trust
Association of British Clinical Diabetologists

Unknown

Randomisation to Endobarrier Alone Versus With Incretin Analogue in SustainEd Diabesity (REVISE-Diabesity)

Obesity | Type 2 Diabetes | Diabesity

United Kingdom
GlaxoSmithKline
PPD

Withdrawn

Albiglutide Versus Placebo Added-on to Basal-Bolus Insulin Therapy in Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2
Hvidovre University Hospital

Unknown

The Effect of GLP-1 on Postprandial Glucagon Secretion Independent of The Gastric Emptying Rate (ALFA-1)

Type 1 Diabetes
Peking Union Medical College Hospital
National Institute for Biomedical Imaging and Bioengineering (NIBIB)

Unknown

68Ga-NOTA-exendin-4 PET/CT for the Localization of Insulinoma and Diagnosis of Nesidioblastosis

Insulinoma | Nesidioblastosis

China
Merck Sharp & Dohme LLC

Completed

Evaluation of the Glucoregulatory Effects of Glucagon-like Peptide-1 Receptor (GLP-1 Receptor) Activation in Participants With Type 2 Diabetes Mellitus (MK-0000-222)

Type 2 Diabetes Mellitus
Mayo Clinic
Astellas Pharma US, Inc.; University of Nebraska; Lantheus Medical Imaging

Completed

Effects of Hyperglycemia on Myocardial Perfusion in Humans With and Without Type 2 Diabetes (GLP-1)

Coronary Artery Disease | Diabetes Mellitus Type 2

United States
Amsterdam UMC, location VUmc

Completed

Effects of Glucagon Like Peptide-1(GLP-1) and Liraglutide on Brain Satiety and Reward Circuits and Feeding Behavior in Diabetes (LIBRA)

Obesity | Type 2 Diabetes

Netherlands
University Hospital, Basel, Switzerland

Completed

Whole Body 111In-exendin-4 Imaging Study in Insulinoma Patients

Hypoglycemia | Hyperinsulinism | Insulinoma

Switzerland
Ligand Pharmaceuticals
Medpace, Inc.; Beckloff Associates, Inc.

Completed

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LGD-6972 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States
University of Virginia
Novo Nordisk A/S

Unknown

Study of Glucagon, Ghrelin and Growth Hormone as Counterregulatory Hormones

Healthy

United States
University Hospital, Gentofte, Copenhagen
Merck Sharp & Dohme LLC

Completed

Endothelial and Metabolic Effects of Glucagon-like Peptide-1 (GLP-1) in Coronary Circulation in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Denmark

Search clinical trials for: Glucagon receptor antagonist

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tunisia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations